ES2098253T3 - Utilizacion de retinoides para invertir la atrofia de la piel inducida por glucocorticoides. - Google Patents

Utilizacion de retinoides para invertir la atrofia de la piel inducida por glucocorticoides.

Info

Publication number
ES2098253T3
ES2098253T3 ES90309510T ES90309510T ES2098253T3 ES 2098253 T3 ES2098253 T3 ES 2098253T3 ES 90309510 T ES90309510 T ES 90309510T ES 90309510 T ES90309510 T ES 90309510T ES 2098253 T3 ES2098253 T3 ES 2098253T3
Authority
ES
Spain
Prior art keywords
retinoids
induced skin
skin atrophy
glucocorticoid
reverse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90309510T
Other languages
English (en)
Inventor
Albert M Kligman
James A Mezick
Robert J Capetola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Application granted granted Critical
Publication of ES2098253T3 publication Critical patent/ES2098253T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Dental Preparations (AREA)
  • Pens And Brushes (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA A LA ADMINISTRACION TOPICA DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE PRODUCTOS DE RETINOL PARA INVERTIR LOS EFECTOS DE ATROFIA EN LA PIEL INDUCIDOS POR GLUCOCORTICOIDES.
ES90309510T 1989-08-31 1990-08-30 Utilizacion de retinoides para invertir la atrofia de la piel inducida por glucocorticoides. Expired - Lifetime ES2098253T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/401,362 US5019569A (en) 1986-11-03 1989-08-31 Reversal of glucocorticoid-induced skin atrophy

Publications (1)

Publication Number Publication Date
ES2098253T3 true ES2098253T3 (es) 1997-05-01

Family

ID=23587438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90309510T Expired - Lifetime ES2098253T3 (es) 1989-08-31 1990-08-30 Utilizacion de retinoides para invertir la atrofia de la piel inducida por glucocorticoides.

Country Status (13)

Country Link
US (1) US5019569A (es)
EP (1) EP0415766B1 (es)
JP (1) JP3061628B2 (es)
AT (1) ATE147265T1 (es)
AU (1) AU634807B2 (es)
DE (1) DE69029625T2 (es)
DK (1) DK0415766T3 (es)
ES (1) ES2098253T3 (es)
GR (1) GR1000723B (es)
IE (1) IE903154A1 (es)
PT (1) PT95150B (es)
SG (1) SG50453A1 (es)
ZA (1) ZA906931B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5254343A (en) * 1991-03-19 1993-10-19 Bristol-Myers Squibb Company Reduction of cutaneous atrophy
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia
CA2129114A1 (en) * 1992-02-07 1993-08-19 Albert M. Kligman Methods of treating inflammatory dermatoses
AU684470B2 (en) * 1992-09-11 1997-12-18 Stb Family Limited Partnership Method and composition for the treatment of hair loss
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US6380255B1 (en) 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
UA48212C2 (uk) * 1996-01-31 2002-08-15 Сергей Дмітрієвіч БУРЛАКОВ Антиглюкокортикоїдний лікарський засіб
FR2760362B1 (fr) * 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
US6008254A (en) 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
NO326950B1 (no) * 2006-09-20 2009-03-16 Pharma Medico Res Ltd Kombinasjon av et glukokortikoid og et β-syklodekstrin konjugert vitamin A derivat-kompleks
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
ES2812451T3 (es) 2015-06-18 2021-03-17 Bausch Health Ireland Ltd Composiciones tópicas que comprenden un corticosteroide y un retinoide para tratar la psoriasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
AU610587B2 (en) * 1987-04-06 1991-05-23 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid

Also Published As

Publication number Publication date
SG50453A1 (en) 1998-07-20
EP0415766A2 (en) 1991-03-06
EP0415766A3 (en) 1992-04-08
DE69029625D1 (de) 1997-02-20
DK0415766T3 (da) 1997-01-27
GR1000723B (el) 1992-11-23
AU634807B2 (en) 1993-03-04
ZA906931B (en) 1992-05-27
EP0415766B1 (en) 1997-01-08
PT95150B (pt) 1997-06-30
JPH03141218A (ja) 1991-06-17
GR900100644A (en) 1991-12-30
DE69029625T2 (de) 1997-05-28
US5019569A (en) 1991-05-28
IE903154A1 (en) 1991-03-13
ATE147265T1 (de) 1997-01-15
AU6198790A (en) 1991-03-07
JP3061628B2 (ja) 2000-07-10
PT95150A (pt) 1991-05-22

Similar Documents

Publication Publication Date Title
ES2098253T3 (es) Utilizacion de retinoides para invertir la atrofia de la piel inducida por glucocorticoides.
MX187577B (es) Composiciones para el cuidado de la piel
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
FR2645441B1 (fr) Traitement de l'hyperparathyroidie par l'utilisation de derives de la vitamine d
EP0266992A3 (en) Prevention of glucocorticoid-induced skin atrophy
MX9206851A (es) Sales organicas de n,n'-diacetil cistina, proceso para su preparacion y composicion farmaceutica que las contiene.
PT641343E (pt) Derivados de 4-mercaptoacetilamino-¬2|benzazapinona (3) e a sua utilizacao como inibidores de encefalinase
ATE74003T1 (de) Waessriges pharmazeutisches praeparat.
ES535711A0 (es) Procedimiento para preparar una composicion para el tratamiento topico de acne
MY106263A (en) Method for the treatment or prevention of intrinsically aged skin with retinoids
MX9206915A (es) Composicion para el cuidado de la piel.
IT1231509B (it) Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
PT90784A (pt) Processo para a preparacao de uma composicao de materiais para aplicacao sobre uma superficie corporal ou membral
BR9105260A (pt) Composicao para aplicacao topica na superficie do corpo humano,processos para o tratamento cosmetico do corpo humano e para a producao de uma composicao
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
ATE87476T1 (de) Fluessige orale formulierung.
ITTO930024A0 (it) Composizione per accelerare la rimarginazione di ferite
BR8602511A (pt) Composicao de fragrancia,processo para a sua preparacao processo para aperfeicoar uma composicao,uso e processo para a preparacao de(e)-3-metil-5-(2,2,3-trimetilciclopent-3-en-1-il)pent-4-en-2-ol
FI910308A0 (fi) Vattenloesliga vitamin a preparationer foer applicering pao huden.
ES2032572T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para aplicacion topica sobre la piel.
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
ES2049711T1 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria.
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
PT100896A (pt) Composicao farmaceutica para a neutralizacao da interleuquina-1(il-1) utilizando dsrna's

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 415766

Country of ref document: ES